CIK 0001516551
- Non-accelerated filer
- Smaller reporting company
Skye Bioscience, Inc.
Sign in to watch- Ticker
- SKYE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- Operating
- EIN
- 450692882
- Phone
- +1 858-410-0266
- Business address
- 11250 EL CAMINO REAL, SUITE 100, SAN DIEGO, CA, 92130
- Former names
- Emerald Bioscience, Inc., Nemus Bioscience, Inc., LOAD GUARD LOGISTICS, INC., LOAD GUARD TRANSPORTATION, INC.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $613,506
- in 6 filings
Net −$613,506. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-29 | Charych Deborah H. Director | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2024-02-29 | Jenkins Annalisa Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2024-02-29 | Schwab Andrew J. Director | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2024-02-29 | DALESANDRO MARGARET Director | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2024-02-29 | Ward Keith Wayne Director | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2024-02-29 | TYLE PRAVEEN Director | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2024-02-29 | Diep Tuan Tu Chief Development Officer | Grant or award | +25,000 | 101,833 | ||
| 2024-02-29 | Diep Tuan Tu Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2024-02-29 | ARSENAULT KAITLYN Chief Financial Officer | Grant or award | +25,000 | 209,738 | ||
| 2024-02-29 | ARSENAULT KAITLYN Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2024-02-29 | DHILLON PUNIT Chief Executive Officer | Grant or award | +100,000 | 397,006 | ||
| 2024-02-29 | DHILLON PUNIT Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2024-02-29 | ARSENAULT KAITLYN Chief Financial Officer | Grant or award | +25,000 | 210,738 | ||
| 2024-02-29 | ARSENAULT KAITLYN Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2024-02-29 | DHILLON PUNIT Chief Executive Officer | Grant or award | +100,000 | 397,006 | ||
| 2024-02-29 | DHILLON PUNIT Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2024-01-31 | Schwab Andrew J. Director | Grant or award | +5,206,074 | $2.31 | $12.0M | 7,943,520 |
| 2024-01-31 | 5AM Partners VII, LLC 10% owner | Purchase | +5,206,074 | $2.31 | $12.0M | 7,943,520 |
| 2023-11-06 | Ward Keith Wayne Director | Grant or award · Stock Option (Right to Buy) | +14,110 | 20,001 | ||
| 2023-11-06 | Charych Deborah H. Director | Grant or award · Stock Option (Right to Buy) | +14,110 | 20,001 |
Page 8 of 15 · 292 trades